Lv2
140 积分 2021-03-27 加入
Molecular characteristics and treatment strategy in advanced, EGFR-mutant non-small cell lung cancer with concomitant BRAF variations
10小时前
求助中
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
3个月前
已完结
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
5个月前
已完结
The current and emerging immunotherapy paradigm in small-cell lung cancer
6个月前
已完结
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
6个月前
已完结
Relationship between clinicopathological characteristics and PET/CT uptake in lung cancer: [18F]FAPI versus [18F]FDG
6个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
6个月前
已完结
The current and emerging immunotherapy paradigm in small-cell lung cancer
6个月前
已完结
皖公网安备34019202002308
